AR and COVID-19: In contrast, the AR antagonist proxalutamide was also tested as a possible treatment for COVID-19 in randomized, controlled trials and showed encouraging positive benefits (41, –43), but these findings were met with caution from the scientific community after a retraction statement was issued for one of the publications, citing concerns over randomization (44).